Targeted Immunotherapy for Pediatric Solid Tumors

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2016 May 4

PMID 27141344

Citations 8

Authors

Lisa M Kopp

Emmanuel Katsanis

Affiliations

Soon will be listed here.

Abstract

Metastatic and refractory pediatric solid tumor malignancies continue to have a poor outcome despite the > 80% cure rates appreciated in many pediatric cancers. Targeted immunotherapy is impacting treatment and survival in these aggressive tumors. We review current promising immunotherapeutic approaches in the pediatric oncology solid tumor setting.

Citing Articles

Immunotherapy Associated Neurotoxicity in Pediatric Oncology.

Shalabi H, Nellan A, Shah N, Gust J Front Oncol. 2022; 12:836452.

PMID: 35265526 PMC: 8899040. DOI: 10.3389/fonc.2022.836452.

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.

Lin T, Park J, Long A, Guo H, Cheung N J Immunother Cancer. 2021; 9(9).

PMID: 34497115 PMC: 8438958. DOI: 10.1136/jitc-2021-003114.

Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.

Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J Cancer Sci. 2019; 110(12):3650-3662.

PMID: 31571332 PMC: 6890444. DOI: 10.1111/cas.14206.

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.

Casey D, Lin T, Cheung N Front Oncol. 2019; 9:537.

PMID: 31275859 PMC: 6593481. DOI: 10.3389/fonc.2019.00537.

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies.

Lu Y, Chu H, Wheeler L, Nelson M, Westrick E, Matthaei J Front Oncol. 2019; 9:151.

PMID: 30941303 PMC: 6433934. DOI: 10.3389/fonc.2019.00151.

References

Pedrazzoli P, Secondino S, Perfetti V, Comoli P, Montagna D . Immunotherapeutic Intervention against Sarcomas. J Cancer. 2011; 2:350-6. PMC: 3119402. DOI: 10.7150/jca.2.350. View

Navid F, Santana V, Barfield R . Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 2010; 10(2):200-9. PMC: 2888262. DOI: 10.2174/156800910791054167. View

Kramer K, Kushner B, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P . Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2009; 97(3):409-18. PMC: 3533371. DOI: 10.1007/s11060-009-0038-7. View

Ahmed M, Cheung N . Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2013; 588(2):288-97. DOI: 10.1016/j.febslet.2013.11.030. View

Orentas R, Lee D, Mackall C . Immunotherapy targets in pediatric cancer. Front Oncol. 2012; 2:3. PMC: 3355840. DOI: 10.3389/fonc.2012.00003. View

Cripe T, Ngo M, Geller J, Louis C, Currier M, Racadio J . Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2014; 23(3):602-8. PMC: 4351466. DOI: 10.1038/mt.2014.243. View

Russell H, Strother D, Mei Z, Rill D, Popek E, Biagi E . A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008; 31(9):812-9. DOI: 10.1097/CJI.0b013e3181869893. View

Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K . WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer. 2010; 55(2):352-5. DOI: 10.1002/pbc.22522. View

Mackall C, Rhee E, Read E, Khuu H, Leitman S, Bernstein D . A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008; 14(15):4850-8. PMC: 2497450. DOI: 10.1158/1078-0432.CCR-07-4065. View

10.

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

11.

Kushner B, Cheung I, Modak S, Kramer K, Ragupathi G, Cheung N . Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014; 20(5):1375-82. PMC: 5592799. DOI: 10.1158/1078-0432.CCR-13-1012. View

12.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

13.

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

14.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

15.

Kolb E, Gorlick R, Houghton P, Morton C, Lock R, Carol H . Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50(6):1190-7. DOI: 10.1002/pbc.21450. View

16.

Mulens V, de la Torre A, Marinello P, Rodriguez R, Cardoso J, Diaz R . Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin. 2010; 6(9). DOI: 10.4161.hv.6.9.12571. View

17.

Oue T, Uehara S, Yamanaka H, Takama Y, Oji Y, Fukuzawa M . Expression of Wilms tumor 1 gene in a variety of pediatric tumors. J Pediatr Surg. 2011; 46(12):2233-8. DOI: 10.1016/j.jpedsurg.2011.09.004. View

18.

Dohnal A, Witt V, Hugel H, Holter W, Gadner H, Felzmann T . Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007; 9(8):755-70. DOI: 10.1080/14653240701589221. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T . Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant. 2008; 13(6):746-53. DOI: 10.1111/j.1399-3046.2008.01066.x. View